Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Myelodysplastic Syndromes 26Hematologic Neoplasms 20Lymphoma, Non-Hodgkin 19Multiple Myeloma 18Lymphoma 18Recurrence 15Lymphoma, B-Cell 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Pancreatic Neoplasms 10Ovarian Neoplasms 10Lymphoma, Follicular 10Neoplasm Metastasis 9Melanoma 9Leukemia, Myelomonocytic, Chronic 9Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Osteosarcoma 6

Interventions

Oxaliplatin 10pembrolizumab 8Fluorouracil 8Leucovorin 7Paclitaxel 5Gemcitabine 5Docetaxel 5Capecitabine 5Cyclophosphamide 4Blood Specimen Collection 4zolbetuximab 3fludarabine 3darolutamide 3cemiplimab 3Trastuzumab 3Taxes 3Ramucirumab 3Radiotherapy 3Radiosurgery 3Irinotecan 3trastuzumab deruxtecan 2enzalutamide 2durvalumab 2Standard of Care 2Nivolumab 2Folfox protocol 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma × fludarabine × Clear all
NCT02133196 2026-06-05

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
85 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

NCT05922930 2026-05-06

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
51 enrolled
GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06532799 2024-11-12

BAH250

Essen Biotech

Phase 1/2 Recruiting
75 enrolled
Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡